IRD — Opus Genetics, Inc.
Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was formerly known as Ocuphire Pharma, Inc. Opus Genetics, Inc. was founded in 2018 and is headquartered in Farmington Hills, Michigan.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ
- Employees: 18
- Website: https://opusgtx.com
Latest SEC filings for IRD
- 144 — 2026-10-23
- 144 — 2026-10-23
- 144 — 2026-10-23
- 8-K — 2026-09-11
- 8-K — 2026-09-09
- EFFECT — 2026-08-17
- SCHEDULE 13G/A — 2026-08-14
- SCHEDULE 13G/A — 2026-08-14
- S-3 — 2026-08-07
- 8-K — 2026-08-06
Latest IRD news
- — Opus Genetics Announces FDA Approval of Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia (GlobeNewswire Inc.)
- — Opus Genetics to Present at the Chardan Annual Healthcare Conference (globenewswire.com)
- — Opus Genetics, Inc. (NASDAQ:IRD) Receives Consensus Recommendation of “Moderate Buy” from Brokerages
Educational tool only — not investment advice.